多药耐药基因表达检测在白血病治疗中的应用研究  

STUDY OF MDR1 IN CHEMOTHERAPY OF ACUTE LEUKEMIAS

作　　者：杨建峰[1] 秦良宜[1] 刘惠杰[1] 

机构地区：[1]江苏省连云港市第一人民医院,江苏连云港222002

出　　处：《白血病．淋巴瘤》2001年第2期95-97,共3页Journal of Leukemia & Lymphoma

摘　　要：目的 :研究 MDR1基因表达与白血病化疗疗效的关系。方法 :应用反转录聚合酶链反应 (RT- PCR)技术对 32例临床标本和 10例正常人进行了 MDR1基因表达检测。并结合患者对化疗药物的敏感性及化疗效果进行比较分析。结果 :在白血病患者中 MDR1基因表达量越高 ,耐药性越强 ,疗效越差。且复发患者 MDR1基因表达明显高于初发患者。结论 :MDR1介导的耐药是白血病多药耐药的主要机制 ,与白血病化疗药物的敏感性有较好的相关性。对指导白血病化疗效果评价具有良好的应用前景。Objective:To investigate the relationship between MDR1 gene expression and the effect of chemotherapy in acute leukemia.Methods:The MDR1 gene of 32 clinical samples and 10 normal samples was detected with RT-RCR.The relationship between MDR1 gene expression and sensitivty of patients to chemotherapy medicines was evaluated.Results:The stronger the resistance was the worse the effects would be and the higher of MDR1 in relapsed patients.Conclusion:The resistance induced by MDR1 is the main mechanism of multidrug resistance in acute leukemia.MDR1 is promising in derecting chemotherapy and evaluating the effect of chemotherapy.

关 键 词：MDR1 化疗 白血病 治疗 

分 类 号：R733.7[医药卫生—肿瘤]